<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1008</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2025-20-1-88-94</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND TREATMENT CHOICE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ И СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИ: ДИАГНОСТИКА И ВЫБОР ТАКТИКИ ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Burkitt lymphoma with heart involvement: features of diagnosis, treatment and follow-up</article-title><trans-title-group xml:lang="ru"><trans-title>Лимфома Беркитта с поражением сердца: особенности диагностики, лечения и катамнестического наблюдения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-8297-3629</contrib-id><name-alternatives><name xml:lang="en"><surname>Radzhabova</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Раджабова</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125993; Build. 1, 2 / 1 Barrikadnaya St.; Moscow</p></bio><bio xml:lang="ru"><p>125993;  ул. Баррикадная, 2 / 1, стр. 1; Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Osipova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Осипова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>420138; 140 Orenburgsky Tract St.; Kazan</p></bio><bio xml:lang="ru"><p>420138; ул. Оренбургский тракт, 140; Казань</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1469-2365</contrib-id><name-alternatives><name xml:lang="en"><surname>Valiev</surname><given-names>T. T.</given-names></name><name xml:lang="ru"><surname>Валиев</surname><given-names>Т. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Timur Teymurazovich Valiev</p><p>125993; Build. 1, 2 / 1 Barrikadnaya St.; 155522; 24 Kashirskoe Shosse; 119991; Build. 2, 8 Trubetskaya St.; Moscow</p></bio><bio xml:lang="ru"><p>Тимур Теймуразович Валиев</p><p>125993;  ул. Баррикадная, 2 / 1, стр. 1; 155522; Каширское шоссе, 24; 119991; ул. Трубецкая, 8, стр. 2; Москва</p></bio><email>timurvaliev@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-5457-6530</contrib-id><name-alternatives><name xml:lang="en"><surname>Turkiya</surname><given-names>L. R.</given-names></name><name xml:lang="ru"><surname>Туркия</surname><given-names>Л. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>155522; 24 Kashirskoe Shosse; Moscow</p></bio><bio xml:lang="ru"><p>155522; Каширское шоссе, 24; Москва</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karimova</surname><given-names>L. R.</given-names></name><name xml:lang="ru"><surname>Каримова</surname><given-names>Л. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>420138; 140 Orenburgsky Tract St.; Kazan</p></bio><bio xml:lang="ru"><p>420138; ул. Оренбургский тракт, 140; Казань</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mikhailova</surname><given-names>S. N.</given-names></name><name xml:lang="ru"><surname>Михайлова</surname><given-names>С. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>155522; 24 Kashirskoe Shosse; Moscow</p></bio><bio xml:lang="ru"><p>155522; Каширское шоссе, 24; Москва</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Children’s Republican Clinical Hospital, Ministry of Health of the Republic of Tatarstan</institution></aff><aff><institution xml:lang="ru">ГАУЗ «Детская республиканская клиническая больница Минздрава Республики Татарстан»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России&#13;
(Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-03-19" publication-format="electronic"><day>19</day><month>03</month><year>2025</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>88</fpage><lpage>94</lpage><history><date date-type="received" iso-8601-date="2025-03-20"><day>20</day><month>03</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-03-20"><day>20</day><month>03</month><year>2025</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/1008">https://oncohematology.abvpress.ru/ongm/article/view/1008</self-uri><abstract xml:lang="en"><p>   Burkitt lymphoma (BL) is a highly aggressive non‑Hodgkin’s lymphoma that characterizes by affecting multiple organs and systems, which explains the diagnosis of the disease at an advanced stage upon the patient’s first medical visit. Heart involvement as part of bL dissemination is extremely rare (2–5 %), but significantly impacts the clinical course, treatment and follow‑up. Heart involvement in bL can manifest as pericardial effusion, myocardial dysfunction or subsequent development of cardiogenic shock. diagnostics of BL with heart involvement should include electrocardiography, echocardiography, N‑terminal fragment of the brain natriuretic propeptide (NT‑proBNP) blood level, myocardial damage markers (troponin I / T), and, if necessary, can include more high‑precision methods – magnetic resonance / computed tomography with intravenous contrast. Timely diagnosis and programmed treatment with rituximab can achieve long‑term survival for BL patients, including advanced stages with heart involvement.</p></abstract><trans-abstract xml:lang="ru"><p>   Лимфома Беркитта (ЛБ) характеризуется высокоагрессивным клиническим течением с поражением многих органов и систем, что объясняет диагностику заболевания в продвинутой стадии на этапе 1‑го обращения пациента за медицинской помощью. Вовлечение в опухолевый процесс сердца в рамках диссеминации ЛБ встречается крайне редко (2–5 %), однако такое событие существенно влияет на клиническую картину, комплексное лечение и последующее наблюдение. При поражении сердца могут быть выявлены перикардиальный выпот, миокардиальная дисфункция с развитием кардиогенного шока. Диагностика поражения сердца при ЛБ включает электрокардиографию, эхокардиографию, исследование уровня N‑терминального фрагмента мозгового натрийуретического пропептида (NT‑proBNP) в крови, маркеров повреждения миокарда (тропонин I / Т), а также при необходимости высокоточные методы – магнитно‑резонансную / компьютерную томографию сердца с внутривенным контрастированием. Своевременная диагностика и программная химиотерапия с включением ритуксимаба позволяют получить высокие показатели многолетней выживаемости при ЛБ, в том числе при диссеминированных стадиях с поражением сердца.</p></trans-abstract><kwd-group xml:lang="en"><kwd>burkitt lymphoma</kwd><kwd>heart involvement</kwd><kwd>children</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфома Беркитта</kwd><kwd>поражение сердца</kwd><kwd>дети</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was performed without external funding</funding-statement><funding-statement xml:lang="ru">Работа выполнена без спонсорской поддержки</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tzani A., Doulamis I.P., Mylonas K.S. et al. Cardiac tumors in pediatric patients : a systematic review. World J Pediatr Congenit Heart Surg 2017;8(5):624–32. DOI: 10.1177/2150135117723904</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Uzun O., Wilson D.G., Vujanic G.M. et al. Cardiac tumours in children. Orphanet J Rare Dis 2007;2:11. DOI: 10.1186/1750­1172­2­11</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bruce C.J. Cardiac tumours: diagnosis and management. Heart 2011;97(2):151–60. DOI: 10.1136/hrt.2009.186320</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dozzo M., Carobolante F., Donisi P.M. et al. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 2016;8:11–29. DOI: 10.2147/AHMT.S94170</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Toma P., Granata C., Rossi A., Garaventa A. Multimodality imaging of Hodgkin disease and non­Hodgkin lymphomas in children. Radiographics 2007;27(5):1335–54. DOI: 10.1148/rg.275065157</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Valiev T.T. Modern strategy for the diagnosis and treatment of non-Hodgkin’s lymphomas in children. Abstract dis. … doctor of medical sciences. Moscow, 2014. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Валиев Т.Т. Современная стратегия диагностики и лечения неходжкинских лимфом у детей. Автореф. дис. … д­-ра мед. наук. М., 2014.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Tao T.Y., Yahyavi­Firouz­Abadi N., Singh G.K., Bhalla S. Pediatric cardiac tumors: clinical and imaging features. Radiographics 2014;34(4):1031–46. DOI: 10.1148/rg.344135163</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Armenian S.H., Hudson M.M., Mulder R.L. et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):e123–36. DOI: 10.1016/S1470­2045(14)70409­7</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lipshultz S.E., Adams M.J., Colan S.D. et al. Long-­term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association [published correction appears in Circulation 2013;128(19):e394]. Circulation 2013;128(17):1927–95. DOI: 10.1161/CIR.0b013e3182a88099</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Gómez­Prieto P., López T., Moreno M. et al. Early detection of chemotherapy­induced cardiotoxicity in hematological patients: a prospective study. Blood 2016;128(22):5988. DOI: 10.1182/blood.V128.22.5988.5988</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ohtani K., Fujino T., Ide T. et al. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline­ induced cardiotoxicity. Clin Res Cardiol 2019;108(6):600–11. DOI: 10.1007/s00392­018­1386­0</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Nakayama T., Oshima Y., Kusumoto S. et al. Clinical features of anthracycline­induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: a single­center, retrospective observational study. EJHaem 2020;1(2):498–506. DOI: 10.1002/jha2.110</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Plana J., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15(10):1063–93. DOI: 10.1093/ehjci/jeu192</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Armstrong G.T., Joshi V.M., Ness K.K. et al. Comprehensive echocardiographic detection of treatment­related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015;65: 2511–22. DOI: 10.1016/j.jacc.2015.04.013</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Marwick T.H. Cancer therapy­related cardiac dysfunction: unresolved issues. Can J Cardiol 2016;32(7):842–6. DOI: 10.1016/j.cjca.2016.05.001</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Tocchetti C.G., Cadeddu C., Di Lisi D. et al. From molecular mechanisms to clinical management of antineoplastic drug­induced cardiovascular toxicity : a translational overview. Antioxid Redox Signal 2019;30(18):2110–53. DOI: 10.1089/ars.2016.6930</mixed-citation></ref></ref-list></back></article>
